332 related articles for article (PubMed ID: 35729608)
21. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
Kitajima K; Miyoshi Y
Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
[TBL] [Abstract][Full Text] [Related]
22. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
[TBL] [Abstract][Full Text] [Related]
23. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
24. PET Imaging for Breast Cancer.
Fowler AM; Cho SY
Radiol Clin North Am; 2021 Sep; 59(5):725-735. PubMed ID: 34392915
[TBL] [Abstract][Full Text] [Related]
25. Advantages and limitations of FDG PET in the follow-up of breast cancer.
Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
[TBL] [Abstract][Full Text] [Related]
26. PET/MRI of the breast.
Plecha DM; Faulhaber P
Eur J Radiol; 2017 Sep; 94():A26-A34. PubMed ID: 28549570
[TBL] [Abstract][Full Text] [Related]
27. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.
Siggelkow W; Rath W; Buell U; Zimny M
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S118-24. PubMed ID: 15146295
[TBL] [Abstract][Full Text] [Related]
28. Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.
Sheikhbahaei S; Mena E; Pattanayak P; Taghipour M; Solnes LB; Subramaniam RM
PET Clin; 2017 Jan; 12(1):105-118. PubMed ID: 27863562
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging using PET and SPECT for identification of breast cancer subtypes.
Liu H; Chen Y; Wu S; Song F; Zhang H; Tian M
Nucl Med Commun; 2016 Nov; 37(11):1116-24. PubMed ID: 27438531
[TBL] [Abstract][Full Text] [Related]
30. Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma.
Wright CL; Maly JJ; Zhang J; Knopp MV
PET Clin; 2017 Jan; 12(1):63-82. PubMed ID: 27863567
[TBL] [Abstract][Full Text] [Related]
31. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography and neoadjuvant therapy of breast cancer.
Cochet A; Generali D; Fox SB; Ferrozzi F; Hicks RJ
J Natl Cancer Inst Monogr; 2011; 2011(43):111-5. PubMed ID: 22043055
[TBL] [Abstract][Full Text] [Related]
33. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
34.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
35. [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.
Seifert R; Küper A; Tewes M; Heuschmid M; Welt A; Fendler WP; Herrmann K; Decker T
Oncol Res Treat; 2021; 44(7-8):400-407. PubMed ID: 34102639
[TBL] [Abstract][Full Text] [Related]
36. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
[TBL] [Abstract][Full Text] [Related]
37. The pivotal role of FDG-PET/CT in modern medicine.
Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
[TBL] [Abstract][Full Text] [Related]
38. Metabolic positron emission tomography imaging in cancer detection and therapy response.
Zhu A; Lee D; Shim H
Semin Oncol; 2011 Feb; 38(1):55-69. PubMed ID: 21362516
[TBL] [Abstract][Full Text] [Related]
39. Clinical applications of positron emission tomography-computed tomography in oncology.
Kumar R; Halanaik D; Malhotra A
Indian J Cancer; 2010; 47(2):100-19. PubMed ID: 20448371
[TBL] [Abstract][Full Text] [Related]
40. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]